

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known

Application Number	10/057,620
Filing Date	October 25, 2001
First Named Inventor	SCARIA
Art Unit	1632
Examiner Name	Dave T. Nguyen
Attorney Docket Number	5046US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US-4,784,950	11-15-1998	ZymoGenetics, Inc.	
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			
	8	US-			
	9	US-			
	10	US-			
	11	US-			
	12	US-			
	13	US-			
	14	US-			
	15	US-			
	16	US-			
	17	US-			
	18	US-			
	19	US-			
	20	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	21	EP 0 775 750	05-28-1997	Immuno AG		
WJ	22	WO 97/20043	06-05-1997	ZymoGenetics, Inc.		
	23	WO 00/23116	04-27-2000	Avigen, Inc.		
WJ	24	WO 01/70763	09-27-2001	The Children's Hospital of Philadelphia		
	25					
	26					
	27					
	28					
	29					


Examiner Signature

Date Considered

6/24/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO-9199

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/057,620
Filing Date	October 25, 2001
First Named Inventor	SCARIA
Art Unit	1632
Examiner Name	Dave T. Nguyen
Attorney Docket Number	5046US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M	31	MILLER, G. et al., "Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia", Gene Therapy, Volume 2, Number 10: pps. 736-742, 1 December 1995	
	32	SHAH, A.M. et al., "Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII", Proceedings of the National Academy of Sciences, USA, Volume 95, Number 8: pps. 4229-4234, 14 April 1998	
	33	ARKIN S. et al., "Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors: Results of the NovoSeven emergency-use program", Database BIOSIS Online, Biosciences Information Service, Database Accession No. PREV1999900229958 XP002228408 abstract & HAEMOSTASIS, Volume 28, Number 2: pps. 83-98, March 1998	
	34	ROMAN, Drews et al., "Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin", Database BIOSIS Online, Biosciences Information Service, Database Accession No. PREV199698601105 XP 002228408 abstract & PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, Volume 92, Number 23: pps. 10462-10466, 1995	
	35	HART, C E et al., "Characterization of a cDNA coding for human factor VII", Database Medline Online, Database Accession No. NLM3488420 XP002228410 abstract & PROC NATL ACAD SCI, USA, Volume 83, pps 2412-2416, 1986	
	36	PARIS, MARGARITIS et al., "Long-term expression of activated FVII in vivo following AAV-mediated liver gene transfer: Implications for treatment with continuous infusion of recombinant activated FVII", Database BIOSIS Online, Biosciences Information Service, Database Accession No. PREV200200220527 XP 002228411 abstract * BLOOD, Volume 98, No. 11, Part 1, pps. 696a, 16 November 2001	

Examiner Signature		Date Considered	6/24/08
--------------------	--	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.